Biomarkers and Drug Discovery: Allopregnanolone from Neuromodulator to Rapid-Acting Antidepressant

Grand Rounds

Event Info

Breadcrumb

  1. Events
  2. Grand Rounds
  3. Biomarkers and Drug Discovery: Allopregnanolone from Ne...

Biomarkers and Drug Discovery: Allopregnanolone from Neuromodulator to Rapid-Acting Antidepressant


13November

Event Info
Category Date and Time
  • Wednesday, November 13, 2019
  • 01:00 PM - 02:00 PM
Topic and Speaker
  • Biomarkers and Drug Discovery: Allopregnanolone from Neuromodulator to Rapid-Acting Antidepressant
  • Graziano Pinna PhD
    • Associate Professor
    • Department of Psychiatry
    • University of Illinois at Chicago College of Medicine
    Graziano Pinna

Location
  • School of Public Health / Psychiatric Institute (SPHPI)
  • 1601 W. Taylor St.
  • Chicago IL 60612
Conference Room
  • 109 (Auditorium)
Video Recording
Event Details

Graziano Pinna received a PhD in Neuroendocrinology, Free University of Berlin, Germany and a Laura of Doctor in Neuropharmacology, University of Cagliari, Italy. He is a Research Associate Professor with the Psychiatric Institute, College of Medicine, UIC. He has authored almost 100 articles in impact journals of psychiatry and neuroscience, edited two books, was a guest speaker in numerous national and international meetings and an organizer for drug discovery symposia on mood disorders. Dr. Pinna is a member of the editorial board of numerous neuroscience journals, including Neurobiology of Stress and Neuropharmacology and has received NIH, DOD and VA grants. His research focus on biomarker discovery and scientific achievements in neuropsychopharmacology include the contribution to the discovery of a novel mechanism for SSRI antidepressants and of neurosteroid-based treatment targets with impact for PTSD and depression therapy.


Audience:

Psychiatrists, Neurologists, and other affiliated professionals interested in mental health

Purpose:

To provide current information on research, treatment, and policy issues relating to psychiatry and its adjunct fields

Instructional level:

Advanced

Objectives:

  1. Biomarker discovery as predictors of susceptibility to develop depression and PTSD and how these biomarkers may predict antidepressant treatment response.
  2. A biomarker axis at the interface of the endocannabinoid and neurosteroid system to improve diagnosis of mood disorders.
  3. The mechanism of action of the novel rapid acting antidepressant action of allopregnanolone (i.e., brexanolone/Zulresso).

The University of Illinois at Chicago (UIC) College of Medicine is accredited by the Accreditation Council for Continuing Medical Education ACCME) to provide continuing medical education for physicians.

The University of Illinois at Chicago (UIC) College of Medicine designates this live activity for a maximum of 1credit AMA PRA Category 1 credit(s)TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Continuing Education Units (1) will be available for Social Workers and affiliated reciprocal agencies. Illinois Board License number 159-000112.

The Department of Psychiatry at the University of Illinois at Chicago is approved by the American Psychological Association to sponsor continuing education for psychologists.  The Department of Psychiatry at the University of Illinois at Chicago maintains responsibility for this program and its content. This event is 1 credit hour continuing education.

No member of the planning committee for this activity have reported a relevant relationship with a commercial interest.  There is no conflict of interest and nothing to disclose.

Dr. Pinna has no relevant financial relationship with commercial interests related to this CME activity.

Map